Difference between revisions of "Thrombolytics for acute ischemic stroke"

(See Also)
 
Line 15: Line 15:
 
==Studies Required==
 
==Studies Required==
 
*Physical exam: [[NIH Stroke Scale]]
 
*Physical exam: [[NIH Stroke Scale]]
*Head CT  
+
*[[Head CT]]
 
*CBC (hemoglobin, plt)
 
*CBC (hemoglobin, plt)
 
*PT/PTT/INR
 
*PT/PTT/INR
Line 31: Line 31:
 
===Exclusion Criteria===
 
===Exclusion Criteria===
 
*Historical
 
*Historical
**Stroke or head trauma in previous 3 months
+
**[[Stroke]] or [[head trauma]] in previous 3 months
**Any history of intracranial hemorrhage
+
**Any history of [[intracranial hemorrhage]]
 
**Major surgery in the previous 14 days
 
**Major surgery in the previous 14 days
**GI or urinary tract bleeding in previous 21 days
+
**[[GI bleed|GI]] or [[hematuria|urinary tract]] bleeding in previous 21 days
 
**[[Myocardial infarction]] in previous 3 months
 
**[[Myocardial infarction]] in previous 3 months
 
**Arterial puncture at noncompressible site in previous 7 days
 
**Arterial puncture at noncompressible site in previous 7 days
Line 41: Line 41:
 
**Only minor and isolated neurologic signs
 
**Only minor and isolated neurologic signs
 
**[[Seizure]] at stroke onset
 
**[[Seizure]] at stroke onset
*Persistent SBP >185 or DBP >110 despite treatment
+
*Persistent [[hypertension|SBP >185]] or DBP >110 despite treatment
*Use of direct thrombin inhibitors or direct factor Xa inhibitors with elevated aPTT, INR, or factor Xa assay
+
*Use of direct thrombin inhibitors (e.g. [[dabigatran]], [[argatroban]]) or direct factor Xa inhibitors (e.g. [[rivaroxaban]], [[apixaban]]) with elevated aPTT, INR, or factor Xa assay
*Active bleeding or acute trauma (fracture) on exam
+
*Active bleeding or acute [[trauma]] ([[fracture]]) on exam
 
*Labs
 
*Labs
 
**Platelets <100K
 
**Platelets <100K
Line 49: Line 49:
 
**INR >1.7 or PT >15 sec if on warfarin
 
**INR >1.7 or PT >15 sec if on warfarin
 
**Elevated PTT if on heparin
 
**Elevated PTT if on heparin
*Head CT
+
*[[Head CT]]
**Evidence of hemorrhage
+
**Evidence of [[ICH|hemorrhage]]
 
**Evidence of multilobar infarction with hypodensity involving >33% of cerebral hemisphere
 
**Evidence of multilobar infarction with hypodensity involving >33% of cerebral hemisphere
**Intracranial neoplasm, AVM, or aneurysm
+
**Intracranial neoplasm, [[AVM]], or aneurysm
 
*Use of dabigatran within 48hrs is relative contraindication
 
*Use of dabigatran within 48hrs is relative contraindication
  
 
===Relative Exclusion Criteria===
 
===Relative Exclusion Criteria===
 
*Minor or rapidly improving stroke symptoms
 
*Minor or rapidly improving stroke symptoms
*Pregnancy
+
*[[Pregnancy]]
 
*[[Seizure]] at onset with postictal residual neuro impairments
 
*[[Seizure]] at onset with postictal residual neuro impairments
  
Line 69: Line 69:
 
**Combination of both previous stroke and DM
 
**Combination of both previous stroke and DM
 
**NIHSS score >25
 
**NIHSS score >25
**Oral anticoagulant use regardless of INR
+
**Oral [[anticoagulant]] use regardless of INR
  
 
==Administration==
 
==Administration==

Latest revision as of 22:44, 1 October 2019

Background

see list of all thrombolytic trials in CVA for more details

NINDS Trial (treated within 3hrs)

Benefits:

  • 12% absolute risk reduction benefit (NNT = 8-9) at 3 months
  • Lower percentage of patients who left hospital severely disabled
  • Comparable 3-month mortality rate (even with increased rate of ICH)

Risks:

  • 1% increase in mortality
  • 5% increase in nonfatal intracranial hemorrhage

ECASS Trial (treated within 4.5hrs)

  • Confirmed NINDS findings even when therapeutic window extended to 4.5hr
  • As a result AHA/ASA now recommends tPA for patients presenting up to 4.5hr after symptom onset

Studies Required

  • Physical exam: NIH Stroke Scale
  • Head CT
  • CBC (hemoglobin, plt)
  • PT/PTT/INR
    • Only need to wait for result if suspicion of abnormal value, patient has received heparin or warfarin, or use of anticoagulants is unknown
  • Glucose
  • ECG
  • Urine pregnancy (pregnancy is relative contraindication)

tPA <3hr

Inclusion Criteria

  • Diagnosis of ischemic stroke causing measurable neuro deficit
  • Clear onset (last witnessed well) <3hr (see below for extension to <4.5hr)
  • Age >18yr

Exclusion Criteria

  • Historical
  • Clinical
    • Spontaneously clearing stroke symptoms
    • Only minor and isolated neurologic signs
    • Seizure at stroke onset
  • Persistent SBP >185 or DBP >110 despite treatment
  • Use of direct thrombin inhibitors (e.g. dabigatran, argatroban) or direct factor Xa inhibitors (e.g. rivaroxaban, apixaban) with elevated aPTT, INR, or factor Xa assay
  • Active bleeding or acute trauma (fracture) on exam
  • Labs
    • Platelets <100K
    • Serum glucose <50, >400
    • INR >1.7 or PT >15 sec if on warfarin
    • Elevated PTT if on heparin
  • Head CT
    • Evidence of hemorrhage
    • Evidence of multilobar infarction with hypodensity involving >33% of cerebral hemisphere
    • Intracranial neoplasm, AVM, or aneurysm
  • Use of dabigatran within 48hrs is relative contraindication

Relative Exclusion Criteria

  • Minor or rapidly improving stroke symptoms
  • Pregnancy
  • Seizure at onset with postictal residual neuro impairments

tPA between 3-4.5hrs

Inclusion Criteria

  • Same as for <3hr

Exclusion Criteria

  • All of the above plus:
    • Age >80yr
    • Combination of both previous stroke and DM
    • NIHSS score >25
    • Oral anticoagulant use regardless of INR

Administration

Alteplase

  • NOTE - in stroke, do not give aspirin until 24 hours after giving tPA, as ASA with tPA does not improve outcomes and increases bleed risk[1]
  • Do not give acutely heparin (or any anticoagulation) if giving tPA[2]

Dosing:

  • 0.9mg/kg IV (max 90mg total)
    • 10% of dose is administered as bolus; rest is given over 60min
  • Neuro check Q15min x 2hr
  • No anticoagulation/antiplatelets x 24hr
  • Blood pressure (keep SBP <180, DBP <105)

If SBP is >180-230 or DBP is >120:

  • Nicardipine 5 mg/hr by slow infusion (50 mL/hr) initially; may be increased by 2.5 mg/hr every 15 minutes; not to exceed 15 mg/hr OR
  • Labetalol 10mg IV over 1–2 min; repeat dose q10–20min up to 300mg max OR
  • Labetalol 10mg IV followed by infusion at 2–8 mg/min

If BP not controlled by above measures:

  • Nitroprusside 0.5–10mcg/kg/min
  • Continuous arterial monitoring advised
  • Use with caution in patients with hepatic or renal insufficiency

tPA Complications

See Also

References

  • Hacke W, Kaste M, Bluhmi E, et al: Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. N Engl J Med 359(13): 1317, 2008
  • ACEP/AAN Guidelines
  • AHA/ASA Guidelines
  • Zinkstok SM, Roos YB, ARTIS Investigators . Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet (2012) 380(9843):731–7.10.1016/S0140-6736(12)60949-0.
  • Periprocedural Antithrombotic Treatment During Acute Mechanical Thrombectomy for Ischemic Stroke: A Systematic Review. Rob A. van de Graaf, Vicky Chalos, Gregory J. del Zoppo, Aad van der Lugt, Diederik W. J. Dippel, Bob Roozenbeek. Front Neurol. 2018; 9: 238.